0001213900-26-044139
SEC filingThe company reported net income of $5.9 million for FY 2025, a significant year-over-year improvement, while operating activities consumed cash and the company remains a pre-revenue SPAC focused on completing an initial business combination.
For the fiscal year ended December 31, 2025, Drugs Made In America Acquisition Corp. reported net income of $5.9 million, representing a substantial improvement compared to the prior year. This positive result occurred despite the company having neither engaged in operations nor generated operating revenues to date, highlighting the unique financial dynamics of a special purpose acquisition company in its pre-business combination phase.
The company reported an operating loss of $2.8 million for the period, reflecting the administrative costs associated with maintaining public company status and pursuing acquisition opportunities. As a SPAC without operating businesses, these costs represent the necessary expenses of evaluating potential targets, maintaining regulatory compliance, and managing shareholder communications. Management commentary indicates these costs include share issuance expenses, though the specific breakdown beyond the authoritative financial metrics cannot be detailed further.
Net cash used in operating activities totaled $539 thousand for FY 2025, representing an increase in cash consumption compared to the prior year. This reflects how administrative expenses continue to draw down available resources while the company searches for a suitable acquisition target. The company maintains the ability to seek working capital loans from its sponsor, affiliates, or certain officers and directors to finance transaction costs in connection with an initial business combination, though no such loans were outstanding as of the reporting date.
The company's primary objective remains completing an initial business combination within the required timeframe. Management acknowledges expecting to continue incurring significant costs in pursuit of acquisition plans while noting they cannot assure successful completion of a business combination. The financial results reflect the transitional nature of the SPAC structure, where investment income from trust account assets can create positive net income figures even while operational activities consume cash and the core business purpose remains unfulfilled.
The company faces the inherent challenges of all SPACs operating within their designated timelines, including identifying suitable acquisition targets, negotiating favorable terms, and obtaining necessary approvals. The financial metrics demonstrate the tension between near-term accounting results and longer-term operational goals, with positive net income figures potentially masking the ongoing cash consumption and strategic uncertainty. Investors should consider both the reported financial results and the broader context of the company's search for a transformative business combination that would fundamentally alter its operations and financial profile.